About this trial
This study aim to validate the clinical performances of two newly developed isothermal nucleic acid amplification bioassays modules for EBOV and LASV. Two retrospective studies will be conducted using biobanked patient samples such as plasma samples and buccal swabs already collected by the Centre de Recherche en Virologie, Laboratoire des Fièvres Hémorragiques Virales de Guinée (CRV-LFHVG) as part of their surveillance and outbreak activities. The diagnostic sensitivity and specificity of the EBOV and LASV bioassays modules will be compared to the gold-standard reverse transcriptase polymerase chain reaction (RT-PCR) technologies used in the national reference lab.
Eligibility criteria
Qualifiers
EBOV and LASV test positive and negative biobanked patient samples
Disqualifiers
not applicable
Trial design
Treatments tested in this trial
- FORTIFIEDx and DECIPHER bioassays
Treatment groups
Locations
Sponsors and collaborators
Institute of Tropical Medicine, Belgium
Lead sponsor
National Center for Training and Research of Maferinyah, Guinea
Collaborator
Gamal Abdel Nasser University of Conakry
Collaborator